ABX 1100
Alternative Names: ABX-1100Latest Information Update: 25 Feb 2025
At a glance
- Originator Janssen
- Developer Aro Biotherapeutics
- Class Centyrin drug conjugates; Centyrins; Small interfering RNA
- Mechanism of Action Glycogen synthase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glycogen storage disease type II
Most Recent Events
- 11 Feb 2025 Aro Biotherapeutics completes a phase I clinical trials in Glycogen storage disease type II (In volunteers) in Canada (Parenteral) (NCT06109948)
- 05 Feb 2025 US FDA approves IND application for ABX 1100 in Glycogen storage disease type II
- 05 Feb 2025 Efficacy, pharmacokinetics and adverse event data from a phase I trial in Glycogen storage disease type II released by Aro Biotherapeutics